Infectologia

Vídeo | Atualização sobre COVID-19: a variante Ômicron.

8 Dez, 2021 | 13:13h

COVID-19 Update: Omicron Variant – JAMA

---

Editorial | A variante Ômicron é ruim, mas a resposta global é pior – “A pandemia não vai acabar enquanto a equidade de vacinas continuar sendo empurrada para as margens.”

8 Dez, 2021 | 13:12h

Omicron is bad but the global response is worse – Nature

---

Além da Ômicron: o que está por vir quanto à evolução viral da COVID.

8 Dez, 2021 | 13:11h

Beyond Omicron: what’s next for COVID’s viral evolution – Nature

---

Risco de complicações pós-operatórias após cirurgias eletivas em pacientes com COVID-19 ativa ou resolvida nos EUA – Cirurgia realizada de 0 a 4 semanas após Covid-19 está associada a risco bastante aumentado de complicações pós-cirúrgicas; cirurgia feita de 4 a 8 semanas depois da infecção ainda está associada com risco aumentado de pneumonia.

7 Dez, 2021 | 11:50h

The Risk of Postoperative Complications following Major Elective Surgery in Active or Resolved COVID-19 in the United States – Annals of Surgery

Conteúdos relacionados:

Guideline: SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery

Study from 116 countries suggests surgery should be delayed for at least seven weeks following a COVID-19 diagnosis to reduce mortality risk

ASA Guidance: Preoperative testing for COVID-19 is essential, regardless of vaccination.

Position statement: Perioperative management of post-COVID-19 surgical patients.

Cohort study: Postoperative in-hospital mortality of patients with COVID-19 infection was more than double that in patients without COVID-19

---

Estudo mostra imunogenicidade aumentada com intervalos maiores entre as doses de vacinas de mRNA contra o SARS-CoV-2.

7 Dez, 2021 | 11:47h

Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals – JAMA

 

Comentário no Twitter (fio – clique para saber mais)

1/ Not surprisingly, a longer delay between 1st & 2nd doses of mRNA COVID vaccines (i.e. 6-7 weeks rather than 3-4 weeks) results in better immune responses.https://t.co/XhiU6u0hYb

— Céline Gounder, MD, ScM, FIDSA (@celinegounder) December 3, 2021

 

---

Série de casos com 139 adolescentes e adultos jovens com suspeita de miocardite após vacina de mRNA mostrou que a maioria deles teve curso clínico leve e resolução rápida dos sintomas.

7 Dez, 2021 | 11:46h

Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults – Circulation

Comunicado de imprensa: Young people recover quickly from rare myocarditis side effect of COVID-19 vaccine – American Heart Association

---

Perspectiva | “Na pior das hipóteses, causa desinformação.” Cientistas afirmam que estudos de saúde fracos podem trazer mais prejuízos do que benefícios.

7 Dez, 2021 | 11:44h

‘It’s misinformation at worst.’ Weak health studies can do more harm than good, scientists say – Science

---

O mundo tem as ferramentas necessárias para acabar com a pandemia de coronavírus. Elas só não estão sendo usadas adequadamente.

7 Dez, 2021 | 11:42h

The world has the tools to end the coronavirus pandemic. They’re not being used properly – CNN

---

Cuidado de idosos e pessoas que necessitam de cuidados paliativos com COVID-19: orientação da Australian National COVID-19 Clinical Evidence Taskforce.

7 Dez, 2021 | 11:41h

Care of older people and people requiring palliative care with COVID-19: guidance from the Australian National COVID-19 Clinical Evidence Taskforce – Medical Journal of Australia

---

Revisão de 4.470 casos de síndrome inflamatória multissistêmica em crianças nos EUA.

7 Dez, 2021 | 11:40h

Multisystem Inflammatory Syndrome in Children—United States, February 2020–July 2021 – Clinical Infectious Diseases

Conteúdos relacionados:

WHO issues guidelines on the treatment of children with multisystem inflammatory syndrome associated with COVID-19.

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2.

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

---